Navigation Links
Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Date:8/15/2013

and Brigham and Women's Hospital to research that analyzes real-world data to help enhance patient health and ensure patients with NVAF have additional information about treatments available to help reduce the risk of debilitating and potentially fatal strokes. In addition to this study program, Boehringer Ingelheim launched the GLORIATM-AF registry program in April 2012, a worldwide registry with the aim of understanding the long-term use of OAC therapy in the reduction of NVAF-related stroke risk in a real-world setting.

"Our support of the study program being conducted by Brigham and Women's Hospital is a sign of our shared commitment to help improve healthcare delivery and outcomes for the estimated five million patients with non-valvular atrial fibrillation in the U.S. who are at increased risk for stroke," said Sabine Luik, M.D., senior vice president, medicine & regulatory affairs, U.S. regional medical director, Boehringer Ingelheim Pharmaceuticals, Inc. "As a science-based company, Boehringer Ingelheim considers patient safety and education as top priorities and we remain dedicated to research and education which fosters greater public health."

About Pradaxa® (dabigatran etexilate mesylate) Capsules

Indications and Usage 
Pradaxa® (dabigatran etexilate mesylate) capsules is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

IMPORTANT SAFETY INFORMATION ABOUT PRADAXA

WARNING: DISCONTINUING PRADAXA IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE. Discontinuing PRADAXA places patients at an increased risk of thrombotic events. If anticoagulation with PRADAXA must be discontinued for a reason other than pathological bleeding, consider coverage with another anticoagulant.

CONTRAINDICATIONS 
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
2. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
3. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
4. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
5. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
6. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
7. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
8. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
9. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
10. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
11. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across ... virus, select Meijer pharmacies in Michigan ... to eligible patients, enabling Meijer pharmacists to administer tests and, ... set by a physician participating in the study. ...
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... George Products Company, Inc. has announced the addition ... OASIS Inspection Systems. Florida Metrology, based ... OASIS Inspection Systems is a line of highly accurate ... control departments across the United States. Tim Row of ...
... Sutro Biopharma, a biopharmaceutical company developing both ... properties, today announced that it has appointed Trevor ... Hallam will lead Sutro,s ongoing efforts in the ... platform for the research and development of novel ...
Cached Medicine Technology:Florida Metrology To Distribute OASIS Inspection Systems 2Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer 2
(Date:4/18/2014)... release is available in French . ... revolutionize surgical practice and regenerative medicine. A team led ... Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the ... 13), has just demonstrated that the principle of adhesion ... vivo to repair soft-tissue organs and tissues. This easy-to-use ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2
... , BETHEL, Conn., Dec. 4 MedClean Technologies, Inc. (OTC Bulletin ... stock purchase agreement with Socius Capital Group, LLC, a Delaware limited ... LLC. Pursuant to the Purchase Agreement, MedClean will receive up to ... up to 750 shares of its Series C Preferred Stock, in ...
... , UNION, N.J., Dec. 4 ... its specialty anatomic pathology services with the launch of ... company,s expansion from a regional laboratory to a leading ... full range of specialties including gastroenterology, urology and now ...
... , OKLAHOMA CITY, Dec. 4 PD-Rx Pharmaceuticals, Inc. (Pink Sheets: ... September 30, 2009, a 24% decrease over the same period last ... $133,681 and $80,402, respectively, each a 70% decrease over the same ... pharmacy sector sales. This trend is expected to continue throughout ...
... SEATTLE, Dec. 4 The National Cancer Institute has awarded a ... become the nation,s sole operator of its Cancer Information Service Contact ... Hutchinson Center - nearly tripling the size of its current CIS ... scheduled for March 15, 2010. The Seattle CIS center will remain ...
... School of Medicine (BUSM) researchers at the Slone Epidemiology Center ... have a reduced incidence of uterine leiomyomata (fibroids). This report, ... current issue of the American Journal of Epidemiology . ... are two to three times more common among black women ...
... ... support Joint Commission initiative to establish standards for language access in healthcare organizations. ... ... information, drug data solutions, and patient education materials for healthcare institutions, understands the ...
Cached Medicine News:Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 3Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3Health News:PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings 2Health News:Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service 2Health News:Researchers find increased dairy intake reduces risk of uterine fibroids in black women 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 3
The Fathom Guidewire combines a nitinol hypotube distal segment with advanced microfabrication technology, creating a design that revolutionizes access of the most tortuous vasculature....
... (hepatitis C virus) is a Microparticle Enzyme ... anti-HCV IgG to HCV recombinant proteins in ... EDTA, sodium heparin, lithium heparin, sodium citrate ... with other laboratory results and clinical information, ...
... MasterControl architecture is the power behind ... provides all the essential building blocks ... management system to boost operational efficiency, ... with regulatory and quality standards. Click ...
... systems are automated, easy to operate and ... outside environment by flexible snap-seal pockets which ... viral contamination of the water. Offered in ... can also accommodate bags of various sizes. ...
Medicine Products: